Intertek Launches Comprehensive Inhalation Product Development Services - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Intertek Launches Comprehensive Inhalation Product Development Services

Intertek announced that it is now offering comprehensive services for the development of orally inhaled and intranasal drug products (OINDPs) for both small molecules and biologics. This follows the company’s acquisition of Melbourn Scientific.

The services include formulation, analytical method development and validation, drug product physical characterization, chemistry, manufacturing and controls (CMC) support, stability studies and QC release testing. The company can also provide regulatory affairs consultancy, bioanalysis and extractables and leachables (E&Ls) studies for all types of inhalation medicine products.

There is an increasing demand for more user-friendly drug delivery products, such as OINDP, which can offer improved patient outcomes. The development of these products requires specialist capabilities and test facilities for techniques such as laser particle sizing, aerodynamic particle size distribution (APSD) by impaction (ACI, NGI), spray pattern/plume geometry and delivered dose assessment.

A key challenge in OINDP development is the control of E&Ls. With inhalation products that deliver the drug directly to the lungs, the rubber and plastic inhaler device components are in constant contact with the product formulation. Consequently, there is a potential for substances to leach from the device components into the drug product. Intertek can provide E&L studies supporting OINDP development.

Source: Intertek


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here